Welcome to our dedicated page for XOMA Royalty SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on XOMA Royalty's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into XOMA Royalty's regulatory disclosures and financial reporting.
Morgan Stanley and Morgan Stanley Investment Management Inc. report that they are no longer significant owners of XOMA Royalty Corp common stock. Each reporting person discloses 0 shares beneficially owned, with 0.0% of the class, and no sole or shared voting or dispositive power over XOMA shares.
The filing states that, as of the relevant date, both entities have ceased to be beneficial owners of more than five percent of XOMA’s common stock. This updates prior large-holder reports and confirms that Morgan Stanley and its investment management affiliate no longer hold a reportable 5% position in the company.
Morgan Stanley and Morgan Stanley Investment Management Inc. report significant ownership of XOMA Royalty Corp common stock in Amendment No. 3 to a Schedule 13G. Morgan Stanley reports beneficial ownership of 1,686,495 shares, and Morgan Stanley Investment Management Inc. reports 1,685,493 shares, each representing 9.5% of the outstanding common stock. Voting and dispositive powers are reported as shared, with no sole voting or dispositive power. The reporting entities are organized in Delaware and file jointly as a parent holding company and investment adviser, with additional subsidiary detail referenced in Exhibit 99.2.
FMR LLC and Abigail P. Johnson report that they no longer beneficially own any common stock of XOMA Royalty Corporation. As of July 31, 2026, they disclose 0.00 shares beneficially owned, representing 0.0% of the outstanding common stock, with no sole or shared voting or dispositive power.
XOMA Royalty Corporation has a significant shareholder, FMR LLC, which, together with related entities, reports beneficial ownership of 1,605,532.14 shares of common stock, representing 9.1% of the class as of 06/30/2026.
FMR LLC reports sole voting power over 1,599,450.00 shares and sole dispositive power over 1,605,532.14 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 1,605,532.14 shares. Within this position, Fidelity Contrafund holds 962,011.00 shares, or 5.4% of XOMA Royalty Corporation’s outstanding common stock at 06/30/2026, and one or more other persons have the right to receive dividends or sale proceeds from part of these securities.
Vanguard Capital Management LLC filed an amended Schedule 13G reporting its beneficial ownership of XOMA Royalty Corp common stock. As of June 30, 2026, Vanguard reports beneficial ownership of 571,823 shares, representing 3.23% of the outstanding common stock.
Vanguard has sole voting power over 66,658 shares and sole dispositive power over 571,823 shares, with no shared voting or dispositive power. The filing aggregates holdings of Vanguard Capital Management LLC and specified affiliated entities and Vanguard funds over which they exercise voting and/or dispositive power, while excluding other Vanguard affiliates whose ownership is disaggregated under SEC guidance.
The ownership is below the 5% threshold, and Vanguard notes that, although various clients and funds have rights to dividends or sale proceeds, no single other person has an interest in more than 5% of the class through these holdings.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of XOMA Royalty Corp. BlackRock reports beneficial ownership of 685,772 shares, representing 3.9% of the outstanding common stock.
BlackRock reports sole voting power675,657 shares and sole dispositive power685,772 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single person has more than five percent of XOMA’s outstanding common shares.
XOMA Royalty LLC has filed a certification to terminate registration under Section 12(g) or suspend its duty to file reports under Sections 13 and 15(d) of the Exchange Act for certain securities. The action covers its Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock, and Depositary Shares representing interests in its 8.375% Series B Cumulative Perpetual Preferred Stock.
BVF-affiliated funds and accounts reported tendering an aggregate 7,593,303 shares of XOMA Royalty Corp common stock on July 14, 2026, in dispositions pursuant to Ligand Pharmaceuticals’ cash merger. The reporting persons received $39.00 in cash per share plus contingent value rights and report no remaining holdings for these positions.
BVF Partners L.P. and affiliated funds filed Amendment No. 15 to their Schedule 13D for XOMA Royalty Corp, reporting that they no longer beneficially own any shares of the company. This change follows completion of a merger in which Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated, merged with XOMA Royalty Holdings Corporation, leaving the XOMA holding company as a wholly owned subsidiary of Ligand.
Under the merger agreement, each XOMA common share was automatically converted into the right to receive $39.00 per share in cash plus contingent value rights representing potential future cash payments. As of July 14, 2026, the reporting persons’ beneficial ownership fell to 0 shares, or 0% of the outstanding class, and they ceased to be beneficial owners of more than 5% of XOMA’s shares.
XOMA Royalty Corp is removing a class of its securities from Nasdaq listing and registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq filed Form 25 covering depositary shares representing the company’s Series B 8.375% cumulative preferred stock and 8.625% Series A cumulative perpetual preferred stock.
The filing states that Nasdaq has complied with its rules to strike this class from listing and that the issuer has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing voluntary withdrawal of the class from listing and registration.